CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 
 

FGEN's Capital Expenditures Growth by Quarter and Year

Fibrogen Inc 's Capital Expenditures results by quarter and year




FGEN Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.33 1.40 0.42
III Quarter September 0.68 0.87 1.58 0.73
II Quarter June 0.99 0.91 1.70 0.46
I Quarter March 0.59 1.64 0.52 1.75
FY   2.26 3.75 5.20 3.36



FGEN Capital Expenditures third quarter 2023 Y/Y Growth Comment
Fibrogen Inc reported decline in Capital Expenditures in the third quarter 2023 by -21.38% to $ 0.68 millions, from the same quarter in 2022.
The contraction in the third quarter 2023 Fibrogen Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 242.76%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Capital Expenditures growth. While Fibrogen Inc ' s Capital Expenditures fall of -21.38% ranks overall at the positon no. 1280 in the third quarter 2023.




FGEN Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -76.43 % 233.33 % -76.8 %
III Quarter September -21.38 % -44.94 % 116.44 % -57.56 %
II Quarter June 8.79 % -46.47 % 269.57 % -4.17 %
I Quarter March -64.02 % 215.38 % -70.29 % -44.79 %
FY   - -27.88 % 54.76 % -53.2 %

Financial Statements
Fibrogen Inc 's third quarter 2023 Capital Expenditures $ 0.68 millions FGEN's Income Statement
Fibrogen Inc 's third quarter 2022 Capital Expenditures $ 0.87 millions Quarterly FGEN's Income Statement
New: More FGEN's historic Capital Expenditures Growth >>


FGEN Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -62.07 % -11.39 % -42.47 %
III Quarter September -30.91 % -4.4 % -7.06 % 58.7 %
II Quarter June 67.8 % -44.51 % 226.92 % -73.71 %
I Quarter March 78.79 % 17.14 % 23.81 % -3.31 %
FY (Year on Year)   - -27.88 % 54.76 % -53.2 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #175
Overall #1280

Capital Expenditures Y/Y Growth Statistics
High Average Low
3785.06 % 242.76 % -87.19 %
(Sep 30 2017)   (Sep 30 2016)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #175
Overall #1280
Capital Expenditures Y/Y Growth Statistics
High Average Low
3785.06 % 242.76 % -87.19 %
(Sep 30 2017)   (Sep 30 2016)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Fibrogen Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
335.62 % 37.88 % -86.53 %
(Mar 31 2017)  


FGEN's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Fibrogen Inc realized fall in Capital Expenditures from the previous quarter by -30.91% to $ 0.68 millions, from $ 0.99 millions declared in the previous quarter.

This is not huge problem, as Fibrogen Inc 's Capital Expenditures frequently seem to dip in this quarter.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fibrogen Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1183.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #138
Overall #1183
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #138
Overall #1183
Capital Expenditures Q/Q Growth Statistics
High Average Low
335.62 % 37.88 % -86.53 %
(Mar 31 2017)  


FGEN's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Fibrogen Inc realized fall in Capital Expenditures from the second quarter by -30.91% to $ 0.68 millions, from $ 0.99 millions declared in the previous reporting period.

As we look into recent slump in the quarter, we should presume, that usually III. Quarter performance emerge softer in contrast to the quarter before, Prisha Chauhan , Major Pharmaceutical Preparations industry observer from Toronto mentioned.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fibrogen Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1183.


Fibrogen Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 2.60 $ 2.78 $ 2.69 $ 3.74 $ 4.80
Y / Y Capital Expenditures Growth (TTM) -45.86 % -49.55 % -57.28 % -27.86 % 14.14 %
Year on Year Capital Expenditures Growth Overall Ranking # 1103 # 348 # 115 # 483 # 797
Seqeuential Capital Expenditures Change (TTM) -6.51 % 3.27 % -27.99 % -22.13 % -12.88 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1683 # 1267 # 885 # 847 # 1274




Cumulative Capital Expenditures growth Comment
Fibrogen Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Fibrogen Inc 's annual Capital Expenditures fall would be -45.86% year on year to $3 millions.

In the Healthcare sector 150 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 348 to 1103.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
879.9 %
73.2 %
-63.17 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 75
Healthcare Sector # 151
Overall # 1103

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
879.9 %
73.2 %
-63.17 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 234
S&P 500 # 1683
Cumulative Capital Expenditures growth Comment
Fibrogen Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Fibrogen Inc 's annual Capital Expenditures drop would be -45.86% year on year to $3 millions.

In the Healthcare sector 150 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 348 to 1103.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
879.9 %
73.2 %
-63.17 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 75
Healthcare Sector # 151
Overall # 1103

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
879.9 %
73.2 %
-63.17 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 75
Sector # 234
S&P 500 # 1683




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
FGEN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for FGEN's Competitors
Capital Expenditures Growth for Fibrogen Inc 's Suppliers
Capital Expenditures Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen Inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com